Molecular Characterization of c-Abl/c-Src Kinase Inhibitors Targeted against Murine Tumour Progenitor Cells that Express Stem Cell Markers by Kruewel, Thomas et al.
Molecular Characterization of c-Abl/c-Src Kinase
Inhibitors Targeted against Murine Tumour Progenitor
Cells that Express Stem Cell Markers
Thomas Kruewel
1,5., Silvia Schenone
2., Marco Radi
3., Giovanni Maga
4, Astrid Rohrbeck
1,5, Maurizio
Botta
3., Juergen Borlak
1,5*
1Center for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany, 2Department of Pharmaceutical Science, University of Genoa, Genoa, Italy,
3Department of Chemistry and Pharmaceutical Technology, University of Siena, Siena, Italy, 4Institute of Molecular Genetics IMG-CNR, Pavia, Italy, 5Department of
Molecular Medicine and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany
Abstract
Background: The non-receptor tyrosine kinases c-Abl and c-Src are overexpressed in various solid human tumours.
Inhibition of their hyperactivity represents a molecular rationale in the combat of cancerous diseases. Here we examined the
effects of a new family of pyrazolo [3,4-d] pyrimidines on a panel of 11 different murine lung tumour progenitor cell lines,
that express stem cell markers, as well as on the human lung adenocarcinoma cell line A549, the human hepatoma cell line
HepG2 and the human colon cancer cell line CaCo2 to obtain insight into the mode of action of these experimental drugs.
Methodology/Principal Findings: Treatment with the dual kinase inhibitors blocked c-Abl and c-Src kinase activity
efficiently in the nanomolar range, induced apoptosis, reduced cell viability and caused cell cycle arrest predominantly at
G0/G1 phase while western blot analysis confirmed repressed protein expression of c-Abl and c-Src as well as the interacting
partners p38 mitogen activated protein kinase, heterogenous ribonucleoprotein K, cyclin dependent kinase 1 and further
proteins that are crucial for tumour progression. Importantly, a significant repression of the epidermal growth factor
receptor was observed while whole genome gene expression analysis evidenced regulation of many cell cycle regulated
genes as well integrin and focal adhesion kinase (FAK) signalling to impact cytoskeleton dynamics, migration, invasion and
metastasis.
Conclusions/Significance: Our experiments and recently published in vivo engraftment studies with various tumour cell
lines revealed the dual kinase inhibitors to be efficient in their antitumour activity.
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Introduction
Cancer research identified c-Abl and c-Src kinases to be
overexpressed and to be hyperactive in various malignancies.
Consequently, research is being directed towards the synthesis and
characterization of novel inhibitors of these non-receptor tyrosine
kinases which play important roles in various signal transduction
pathways to mediate cellular growth, proliferation, invasion and
metastatic spread [1,2].
Notably, the first approved kinase inhibitor for the treatment of
chronic myeloid leukaemia (CML) was imatinib (Glivec). This drug
inhibits chimeric Bcr/Abl kinase, i.e. a truncated fusion protein
generated by chromosomal translocation of a breakpoint cluster
region (Bcr) with the Abl gene that has also been referred to as the
Philadelphia chromosome in leukaemia patients. Indeed, inhibition
of Bcr/Abl by imatinib prevented hyperproliferation of leukaemic
cells and is considered to be a first line treatment of CML [3,4].
However, prolonged treatment of patients resulted in therapeutic
failures and chemoresistance, in part due to various mutations, such
as the gate-keeper mutation that prevented the binding of imatinib
to the ATP binding site [5]. Thus, a new generation of kinase
inhibitors have been envisioned and research programs amongst
different laboratories pursue the synthesis and evaluation of new
classes of kinase inhibitors in the combat of cancer.
In this regard, the Src non-receptor tyrosine kinases (Src, Fyn,
Yes, Blk, Yrk, Fgr, Hck, Lck and Lyn) received much attention
and are considered to be part of the molecular basis of imatinib’s
resistance [6], particularly as Src kinases remain full activity after
imatinib treatment [7]. To overcome imatinib’s chemoresistance,
dual kinase inhibitors against c-Abl and c-Src were developed and
dasatinib (Sprycel) is the first generation of a new class of dual
kinase inhibitors displaying striking therapeutic benefit [8,9].
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imatinib’s resistance as described in detail elsewhere [10] and
more than 20 clinical trials are on the way to evaluate the
therapeutic benefit of either imatinib and/or dasatinib in the
treatment of solid tumours [11–15]. Notably, inhibition of c-Src
may lead to an improved chemosensitivity as was shown for
patients with pancreatic cancers with resistance against 5-
fluorouracil that blocks thymidylate synthase [16]. Moreover,
recent advances in the treatment of hepatocellular carcinoma
(HCC) with the tyrosine kinase inhibitors sorafenib (Nexavar) or
sunitinib (Sutent) demonstrate the therapeutic value of multikinase
inhibition [17–20].
Taken collectively, there is considerable evidence for c-Src and
c-Abl dual kinase inhibitors to represent an important strategy in
the combat of cancer. The design of novel c-Abl/c-Src inhibitors
on the basis of different molecular scaffolds may improve
therapeutic options in patients refractory to common protocols.
In this regard, our research group carried out extensive studies
on a new family of pyrazolo [3,4-d]pyrimidines which we found to
block c-Abl and c-Src phosporylation efficiently in the nanomolar
range. This new class of inhibitors induce effectively apoptosis,
reduce cell proliferation in different solid tumour cell lines such as
epidermoid carcinoma A431 cells, the breast cancer 8701-BC
cells, the osteosarcoma SaOS-2 cells and the prostate cancer PC3
cells. In addition, this new class of inhibitors were well tolerated in
engraftment experiments with the epidermoid carcinoma cell lines
A431, and evidence has been obtained for these compounds to be
potent inhibitors of angiogenesis due to reduced production of
VEGF [21–24].
Here we report the efficacy and the molecular pharmacology of
17 novel functionalized pyrazolopyrimidines that were studied on
a panel of 11 different murine lung tumour progenitor cell lines
that express stem cell markers and are derived from a cmyc/craf
transgenic mouse model of lung cancer, as recently reported by us
[25]. The dual kinase inhibitors were also tested in the human lung
adenocarcinoma cell line A549, the human hepatoma cell line
HepG2 and the human colon cancer cell line CaCo2. To improve
an understanding of the mode of action of the most active
inhibitors, whole genome expression analysis were carried out and
subjected to advanced computational pathway analysis to enable
generation of hypothesis and to validate further such data by
protein expression studies.
Overall, we report the effectiveness of 17 novel dual kinase
inhibitors on a large panel of epithelial tumour cell lines and
provide novel insight into the mode of action of these
experimental drugs.
Results
Cancer stem cell markers
The murine lung tumour cells A2C12, BetaD5, GammaA3 and
GammaD12 were isolated from mice transgenic for c-Myc and c-
Raf as described recently [26]. For comparison the human lung
cancer cell line A549, the human hepatoma HepG2 and the colon
carcinoma CaCo2 cells were studied as well. Initially, we
investigated the expression of the cancer stem cell markers Cd34,
Cd24a, Cd44, Cd133, Cd90, Podoplanin (Pdpn), Nestin (Nes) and
Discs, large homolog 7 (Drosophila) (Dlg7). As shown in the
supplementary table S1 expression of stem cell markers varied
between the different cell lines, albeit expression was generally
increased when compared to appropriate controls. These cells
were used to investigate the effects of a series of dual kinase
inhibitors on growth and resistance of tumours and to identify
possible candidates for further preclinical development.
c-Abl/c-Src dual kinase inhibitors
As the 17 4-amino-substituted pyrazolo[3,4-d]pyrimidine deriv-
atives 4–5 and 9–23 were ATP-competitive, the dual kinase
inhibitors were tested for kinase inhibition and affinity to c-Abl
and c-Src. The calculated Ki-values for c-Abl ranged in the
nanomolar concentration. However, the affinity to c-Src differed
considerable according to the different substitutes. While Ki-values
were predominantly obtained in a nanomolar range, some were
also at the micromolar range (Table 1). Best inhibitory results were
obtained for Si162 with a Ki of 42 nM and 444 nM for c-Src and
c-Abl, respectively.
For all inhibitors the cytotoxicity was determined by use of the
MTS-assay, that is a colorimetric assay of cell viability and based
on the reduction of a tetrazolium salt (MTS) by a mitochondrial
reductase, at concentrations of 1, 10 and 100 mM after single
treatment for 24 h (data not shown). Based on this initial
screening, the murine tumour-derived cell lines (A2C12, BetaD5,
GammaA3 and GammaD12) and the human tumour cell
lines (A541, CaCo2 and HepG2) were selected for in depth
investigations.
An IC50 for each of the dual kinase inhibitors, as well as for the
approved kinase inhibitors imatinib mesylate and dasatinib, was
determined after treatment for 24 or 96 h. Clear evidence was
obtained for structurally related compounds to differ in their
cytotoxic potential. (Note, the IC50 after single treatment for 24 h
are given in supplementary table S2).
Except for the human hepatoma HepG2 tumour cell line, the
IC50 for lung tumour cells and the human colon carcinoma cell
line CaCo2 were in the range of 3 to 12 mM.
Amongst the individual dual kinase inhibitors Si135 and Si162
were most effective. In the case of Si162 and depending on the
tumour cell line studied the IC50 ranged between 0.8 and 6.4 mM.
However, with the HepG2 cell line an IC50 of 14.5 mM was
calculated (see supplementary table S3 for IC50 values after 96 h).
Cell cycle analysis
After monitoring the cytotoxic potential of the dual kinase
inhibitors, the effects on cell cycle regulation were analyzed by
flow cytometry at IC50 treatment conditions in response to daily
treatment for 96 h.
Notably, those Si-compounds with high potency such as Si162
also induced most significant changes in the cell cycle. Compared
to the vehicle treatment that consisted of DMSO (0.2%) only a
decrease in the S-phase of up to 91% and an increase in G0/G1 of
up to 92% (GammaA3 treated with Si70) was determined. A
similar change was reported for dasatinib after treatment of
various tumour cell lines. Note, this is an approved c-Src and c-Abl
inhibitor [27]. With Si162 an increase in the G2/M phase (up to
72.3%62.8% of all A549 cells) was determined in lung tumour
and hepatoma cancer cell lines, respectively (see supplementary
table S4).
Caspase activity
Accompanied by significant changes in cell cycle regulation
caspase-3/7-activity increased strongly. Caspase activity was
evaluated with the most active inhibitors (Si57, Si135 and
Si162). Clear differences between these experimental dual kinase
inhibitors and the induction of caspase activity was observed. This
difference in response is depicted in Fig. 1.A. Strikingly, after
treatment with Si57 the caspase activity declined in all cell lines,
while treatment with Si135 caused a 10 fold increase in caspase
activity as determined for the BetaD5 and GammaA3 cell lines.
With Si162 caspase activity increased in all tested cell lines up to 3
fold after treatment as determined for GammaD12. After 96 h of
c-Abl/c-Src Inhibitors
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below control values, except for Si135 and the cell line GammaA3
where an increase of about 30% of control was recorded.
Together, these results indicate the high cytotoxic potential of
the tested dual kinase inhibitors. Treatment with the inhibitors led
predominantly to cell cycle arrest in G0/G1, however Si162
caused an arrest in G2/M. This suggests inference of kinase
inhibitors at different phases of the cell cycle, that coincided with
induction of caspase activity.
Western blot analysis
Western blots were carried out with all human (Fig. 2) and
murine (Fig. 3) cell lines after treatments with Si57, Si135 and
Si162 respectively, at IC50 concentrations determined for the 96 h
time point. Compared to vehicle treated controls, the dual kinase
inhibitors repressed protein expression of c-Abl and c-Src up to
90%. Nonetheless, the posttranslational modification of c-Src was
basically unchanged and the level of activated and phosphorylated
c-Src on residue Tyr416 remained equal. However, the lung
tumour cell lines A549 and BetaD5 displayed inhibition of c-Src
autophosphorylation after treatment with Si162. A further
important finding of the Western blot experiments was the
repression of EGFR, an upstream molecule in the signalling
pathway of c-Src and c-Abl. Indeed, its expression was remarkably
reduced after treatment with the dual kinase inhibitors. However,
no changes in the phosphorylation of EGFR residue Tyr992 were
detectable. Contrary to Tyr992, the phosphorylation of residue
Tyr1045 indicates heterogeneity towards cell line and treatment;
likewise, the epidermal growth factor receptor substrate 15
(EPS15) displayed heterogeneity of response to treatment.
An other Src substrate, the focal adhesion kinase (FAK), was
clearly repressed (up to 50%) after treatment with Si162 in lung
cancer cell lines. Equally, the downstream p38 MAPK was 80%
less expressed after treatment. The detection of proteins Cdc2-
p34, c-Fos, hnRNP-K, p53, p73 and STAT5 gave further insight
on the condition of the cells after inhibition of c-Abl and c-Src.
Table 1. Allocation of substituents and their effect on enzyme kinetics of c-Abl and c-Src.
Ki( mM)
Compound R1 R2 R3 c-Abl c-Src
4 (Si 135) SC5H10 NHC6H4mCl CH2CHClC6H5 0.120 NA
5 (Si 142) SCH(CH3)2 NHCH2CH2C6H5 CH2CHClC6H5 0.120 2.000
9 (Si 166) CH3 NHC6H4mF CH2CHClC6H5 0.151 0.338
10 (Si 167) CH3 NHC6H4mCl CH2CHClC6H5 0.500 0.362
11 (Si 20) SC2H5 NHC4H9 CH2CHClC6H5 0.320 0.600
12 (Si 27) SCH3 N(C2H5)2 CH2CHClC6H5 0.440 0.500
13 (Si 34) SCH3 NHCH2C6H5 CH2CHClC6H5 0.260 3.700
14 (Si 81) SCH3 NHCH2C6H5 CH2CHBrC6H5 0.190 1.800
15 (Si 65) SCH3 NHCH2C6H5 CH2CHClC6H4pF 0.250 35.000
16 (Si 66) SCH3 NHCH2CH2C6H5 CH2CHClC6H4pF 0.200 5.300
17 (Si 93) SCH3 NHC6H4mF CH2CHClC6H4pF 0.220 4.510
18 (Si 40) SCH3 NHCH2CH2C6H5 CHCHC6H5 0.450 NA
19 (Si 57) SCH3 NHCH2CH2C6H4pCl CH2CHClC6H5 0.350 25.000
20 (Si 70) SCH3 NHCH2C6H5 CH2CHClC6H4pCl 0.110 3.000
21 (Si 51) H 4-morpholino CH2CHBrC6H5 0.220 NA
22 (Si 104) H NHC6H4mCl CH2CHClC6H4pF 0.180 1.400
23 (Si 162) H NHCH2C6H4oF CH2CHClC6H5pBr 0.444 0.042
Ki values toward isolated Abl and Src were calculated according to the following equation: Ki~ID50= E0z E0 Km(ATP)=S0 ðÞ ½  fg =E0 where E0 and S0 are the enzyme
and the ATP concentrations (0.005 and 0.012 mM. respectively).
doi:10.1371/journal.pone.0014143.t001
Figure 1. Caspase-3/7-activity. Activity of caspases 3 and 7 is shown
in reference to vehicle after treatment with the dual kinase inhibitors
Si57 (white bars), Si135 (grey bars) and Si162 (black bars) for 24 h (A)
and 96 h (B). Caspase activity of vehicle cells was defined as 100%.
doi:10.1371/journal.pone.0014143.g001
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kinase 1 or p34, was reduced up to 95% after treatment. Note, this
kinase plays pivotal roles in G1/S and G2/M transitions [28,29]
and activates c-Src, by phosphorylation of serine and threonine
residues, when cells enter mitosis [30]. Most distinct reduction of
Cdc2 was detected after treatment with Si162, and this finding
agrees well with the observed G2/M arrest of treated cell lines.
Again, Si162 was more potent than Si135 but the level of
heterogenous nuclear ribonucleoprotein K (hnRNP-K), that plays
a role in facilitating c-Src phosphorylation, remained equal after
treatment with Si57 and Si135. Note, c-Src is a substrate of
hnRNP-K [31] and the phosphorylation by c-Src drives the
translational activation of hnRNP-K [32].
The protein expression of the transcription factors c-Fos and
STAT5 was also reduced by approximately 90% and 80%,
respectively for A549. Both are c-Src mediated downstream
targets of EGFR and crucial for tumour progression [33,34]. A
clear induction of p53 could be observed after treatment with
individual dual kinase inhibitors albeit at different level when
different cell lines and treatment conditions were compared. The
antibody targeted against p73 generated moderately detected after
treatment of A549 and CaCo2 tumour cells. The absence of
cleaved PARP product (data not shown) agreed well with the
results obtained for caspase activity which declined after multiple
treatment for 96 h, therefore suggesting that induction of apoptosis
is an initial and timed event.
Whole genome expression analysis
The two most sensitive murine (A2C12 and GammaA3) and the
three human cell lines were treated with the most active dual
kinase inhibitors Si135 and Si162 at IC50 concentrations for 96 h.
Then, microarray experiments were performed and analyzed
using the ArrayTrack software (National Center for Toxicological
Research/FDA, Jefferson, AR, USA). Essentially, the data was
analyzed by two-class unpaired Significance Analysis of Micro-
arrays (SAM). Genes with a False Discovery Rate (FDR),0.01, a
Mean Channel Intensity (MCI).100, Bad Flags less or equal 2
and a Fold Change (FC).2 were considered as significant. Highly
significant changes in gene expression were determined (Table 2),
however neither treatment with Si135 nor Si162 revealed any
alterations in gene expression of the two target kinases c-Abl and c-
Src. After treatment with Si135 approx. 150 genes were
significantly regulated, whereas with Si162 more than 3500 and
500 genes were regulated in the cell lines GammaA3 and A2C12,
respectively while only 75 genes were regulated in CaCo2 cells.
Both murine cell lines shared a relatively large intersection of 259
commonly regulated genes (Fig. 4D), while the human cell lines
responded to this treatment differently. After treatment with
Si135, there was no common gene regulated in any of the human
cancer cell lines tested. Note, the cancer cell lines A549 and
CaCo2 shared regulation of 13 genes in common (Fig. 4A). That is
approx. 16% of all differentially regulated genes in A549 but only
about 5% of those in CaCo2. After treatment with the dual kinase
inhibitor Si162 there were only two genes regulated in common
amongst all three human cell lines, namely Serpine peptidase
inhibitor, clade E, member 2 (Serpine2) and tubulin, alpha 1a
(Tuba1a) (Fig. 4B). The significantly regulated genes were classified
according to their biological functions thereby revealing a
significant change in expression of genes involved in the process
of cell communication and cell cycle regulation. To enable
hypothesis generation and to better understand the biological
significance of differentially expressed genes, specific regulatory
and signalling pathway networks were constructed with the
Ingenuity Pathway Analysis tool (Ingenuity Systems, Mountain
View, CA, USA; www.ingenuity.com).
Indeed, microarray data revealed in lung tumour and hepatoma
cell lines distinct regulations in integrin and FAK (focal adhesion
kinase) signalling, as well as altered actin dynamics (see
supplementary tables S5 and S6). As c-Src and c-ABL play
pivotal roles in cytoskeleton rearrangements, various cellular
functions such as migration, metastasis, invasion and mitosis may
be affected. Specifically FAK is crucial for centrosome function
during mitosis [35] and the increased expression of Gadd45a and
several kinase inhibitors such as p21Cip1, p15Ink4, p16Ink4 and
p19Arf, as well as the repression of Cdc2 (Cdk1), may explain, at
least in part, the effects of dual kinase inhibitors on spindle
formation in mitosis. Furthermore, the gene expression analysis
revealed an upregulation of programmed cell death inducing genes
coding for calpain, p53 apoptosis effector related to PMP-22
(PERP), Caspase 6, p53-induced protein with a death domain
(PIDD), PMA-induced protein 1 (NOXA) and Bcl2-like protein 11
(Bim). In the case of p53, a strong protein induction was confirmed
as well (Fig. 2 and 3) as was activity of caspase 3/7 by flow
cytometry.
The treatment effects of Si135 were less pronounced as
observed with Si162, therefore demonstrating the importance of
the molecular structure in causing different biological effects. After
the treatment with the dual kinase inhibitor the cells predomi-
nantly arrested in G0/G1 phase as determined for GammaA3
where up to 75% of cells remained in this phase. All treated cell
lines displayed a change in expression pattern of genes coding for
proteins of the cytoskeleton and proteins involved in cell growth
and migration which we found to be repressed. Additionally,
treatment with Si135 altered the expression of cell cycle regulators
and inhibited the signal transduction via mitogen activated protein
kinases (MAPK) that was also evidenced for p38 at the protein
level (Fig. 2 and 3). Together, the results suggest the cell cycle
arrest to be in part by induction of kinase inhibitors like p21Cip1
Figure 2. Treatment effects on the protein concentration in
human cell lines. Cells were seeded in various densities in 75 cm
2 cell
culture flasks. After 72 h adhesion, the cells were treated with the dual
kinase inhibitors for 96 h. Culture media enriched with experimental
compounds (IC50 concentrations) was exchanged daily. After harvest,
preparation of SDS extract and SDS-PAGE with an amount of 25 mg
protein, Western blot analyses were carried out.
doi:10.1371/journal.pone.0014143.g002
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caspase activity as part of a programmed cell death.
Secondary effects with the dual kinase inhibitors
The networks around the tyrosine kinases c-Src and c-Abl as
well as EGFR and HGF/c-Met were constructed and analyzed.
Cell line A549 treated with Si162 (see supplementary
figure S1). Treatment of A549 lung cancer cells with Si162
caused induction of a large number of genes, but only a few were
downregulated. It is of considerable importance that transcript
expression of the kinases c-Abl and c-Src were unchanged, while
expression of genes coding for DNA-damage response and
checkpoint regulation were downregulated. Indeed, regulation of
Rad51, essential for homologous recombination as well as breast
cancer 1 (Brca1) and Fanconi anemia, complementation group A
(Fanca) that build DNA repair complexes were found to be
repressed. Further genes associated with DNA repair that were
repressed were DNA-directed polymerase, delta 1, catalytic
subunit (Pold1), origin recognition complex, subunit 1-like (Orc1l)
and topoisomerase (DNA) II binding protein 1 (Topbp1).
Additionally, the cell cycle regulators cell division cycle 2 (Cdc2),
phosphatase cell division cycle 25c (Cdc25c), cyclin-dependent
Figure 3. Treatment effects on the protein concentration in murine cell lines. Cells were seeded in various densities in 75 cm
2 cell culture
flasks. After 72 h adhesion, the cells were treated with the dual kinase inhibitors for 96 h. Culture media enriched with experimental compounds (IC50
concentrations) was exchanged daily. After harvest, preparation of SDS extract and SDS-PAGE with an amount of 25 mg protein, Western blot
analyses were carried out.
doi:10.1371/journal.pone.0014143.g003
Table 2. Significantly differentially regulated genes after treatment with Si135 and Si162.
Si135 Si162
downregulated upregulated downregulated upregulated
A2C12 33 118 212 357
GammaA3 66 79 1139 2453
A549 17 61 472 785
CaCo2 55 193 6 75
HepG2 0 87 707 717
After treatment with Si135 and Si162 at IC50 concentrations for 96 h, whole genome expression analyses were carried out. Microarray data was analyzed with ArrayTrack
software. Significantly differentially regulated genes were determined by two-class unpaired SAM with an FDR,0.01; MCI.100; Bad Flags: 2; FC.2.
doi:10.1371/journal.pone.0014143.t002
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downregulated. Note, the latter kinase is frequently overexpressed
in tumour cells and represents a molecular target in cancer
therapy. The apoptosis inhibitor baculoviral IAP repeat-
containing 5 (Birc5), also known as survivin, which is highly
expressed in lung tumours was significantly repressed upon
treatment with dual kinase inhibitors while members of the Wnt-
pathway such as glycogen synthase 3 beta (Gsk3b) or diacylglycerol
kinase alpha (Dgka), Inositol-polyphosphat-5-phosphatase (Inpp5d)
and prostaglandin-endoperoxide synthase 2 (Ptgs2) were
upregulated, as was expression of Jun, early growth response
(Egr1), Elf3 and Ehf3.
Conversely, genes that are widely overexpressed in tumours like
Mucin 1 (Muc1) [36], the protease cathepsin B (Ctsb) [37] and
integrin, beta 4 (Itgb4) remained upregulated upon treatment with
the dual kinase inhibitor. Molecules that are linked to cell-cell
contact like E-cadherin (Cdh1) and vitronectin (Vtn) were also
induced as was the induction of the p53 inhibitor Mdm2, that binds
to p53 and prevents its activation as part of a negative feedback
autophosphorylation [38]. This demonstrates that Si162 regulates
only certain cancer genes in the A549 tumour cell line within the
c-Src and c-Abl network.
Cell line A2C12 treated with Si162 (see supplementary
figure S2). Treatment of this murine lung cancer cell line with
Si162 did not alter gene expression of the target kinases Abl,
EGFR, Met and Src while an increased protein expression of
tumour suppressor p53 is consistent with the toxic effects caused by
Si162. Downregulation of cyclin A2 (Ccna2), Polo-like kinase 1
(Plk1) and the centromer protein A (Cenpa) which are typically
upregulated in tumour cells to foster cell cycle and mitosis agree
well with the observed cell cycle arrest and demonstrate the
therapeutic effect of these experimental inhibitors. Indeed,
downregulation of ERBB feedback inhibitor receptor 1 (Errfi1),
whose expression is elevated in cell growth, provides further
evidence for this dual kinase inhibitor to cause cell cycle arrest.
Several growth factors were downregulated as well like osteoglycin
(Ogn), pleiotrophin (Ptn) and transforming growth factor, beta 3
(Tgfb3) that in turn regulate transcription factors like serum
response factor (Srf), transforming growth factor beta 1 induced
transcript 1 (Tgfb1i1) and nuclear factor I/B (Nfib). The functional
relationship between Src inhibition and regulation of the receptor
tyrosine kinase platelet-derived growth factor receptor beta (Pdgfrb)
[39] as well as the fibronectin receptor integrin alpha 5 (Itga5) [40]
has been commonly observed in tumour cells. In the network of c-
Abl and c-Src and similar to the observations described for the
human lung cancer cell line A549, an induced expression of Mdm2
and Gadd45a was noted, as was an induction of the matrix
metallopeptidases 3 and 13 (Mmp3 and Mmp13) that are involved
in metastasis to support degradation of extracellular matrix
proteins [41]. Furthermore, treatment with Si162 altered
expression of genes involved in Wnt and Toll-like pathways.
Thus, expression of the receptors toll-like receptor 4 (Tlr4) and
secreted frizzled-related protein 1 (Sfrp1) were upregulated and
might be linked to an induced expression of the cytokines secreted
phosphoprotein 1 (Spp1) and chemokine (C-C motif) ligand 5
(Ccl5). Importantly, expression of chemokine (C-X-C motif) ligand
12 (Cxcl12) which plays an essential role in tumour migration
remained downregulated [42–44].
Cell line GammaA3 treated with Si162 (see supple-
mentary figure S3). Treatment with the dual kinase inhibitor
Si162 resulted in more than 3500 differentially expressed genes and
about 100 molecules in the context of the tyrosine kinases c-Abl,
EGFR, c-Met and c-Src. Additionally, genes involved in DNA
checkpoints (e.g. Brca1) and repair (e.g. Rad51) were significantly
regulated, such as those involved in the G2/M checkpoint.
Cell line CaCo2 treated with Si162 (see supplementary
figure S4). In contrast to the lung cancer cell lines, the human
colon adenocarcinoma cell line CaCo2 differed in its response to
treatment with Si162. Especially metabolic pathways e.g. fatty acid
metabolism was regulated. The network around the tyrosine
kinases shows clear differences to the lung cancer cell lines.
Notably, only induced genes were found in the network around
the target kinases, but included upregulated Ceacam6 and
metastasis-involved molecules such as Mmp1 and Cd44 [45,46].
Additionally, genes coding for the cytoskeleton such as tubulin
alpha 1a (Tuba1a) and vimentin (Vim), a member of the
intermediate filament family, as well as cytokines Spp1 and Ccl20
were increased after treatment with Si162. Notably, expression of
caveolin 1 (Cav1) and AXL receptor tyrosine kinase (Axl)i so f
therapeutic importance as is Cav1, known as tumour suppressor
where it functions as a negative regulator of the Ras-p42/44 MAP
kinase cascade. On the other side, Cav1 also supports the initial
activation in the Ras-ERK signalling by mediating the binding of
integrin subunits on the FYN tyrosine kinase [47,48].
Cell line HepG2 treated with Si162 (see supplementary
figure S5). Treatment of the human hepatocellular carcinoma
cell line HepG2 with Si162 resulted in regulation of p53 and DNA
repair, most notably the G2/M checkpoint. Overall, more than
1400 genes were differentially expressed. Although expression of Src
and Abl were unchanged at the mRNA level several downstream
kinases were regulated and this included downregulated epidermal
growth factor receptor family Erbb4 but induction of Egfr. Further
downregulated receptor tyrosine kinases were platelet-derived
growth factor receptor beta (Pdgfrb) and insulin receptor (Insr).
Expression of the serine/threonine kinase Akt2 was also repressed as
was the gene expression of phosphorylase kinase alpha 2 (Phka2), an
enzyme in carbohydrate metabolism, and phosphoglycerate kinase
that is involved in glycolysis. Notably, treatment of HepG2 with
Si162 induced expression of Fas, Caspase 3 (Casp3) and Bcl 2-like 1
(Bcl2l1), that act as inhibitor or activator of apoptosis depending on
Figure 4. Commonly regulated genes after treatments with the
dual kinase inhibitors. Commonly regulated genes in human cell
lines after treatment with Si135 (A) and Si162 (B), and in murine cell
lines after treatment with Si135 (C)and Si162 (D) were displayed as
venn-diagrams.
doi:10.1371/journal.pone.0014143.g004
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sequence 1 (Mcl1) a member of the proapoptotic Bcl-family was
induced. As observed with the lung cancer cell line, the cell cycle
regulator Cdc2, Fanca and Cdc25c were downregulated, while the
kinase inhibitors Cdkn1a and Cdkn2a as well as cyclin-dependent
kinase 5 (Cdk5) were upregulated as was expression of the p53-
inhibitor Mdm2.
Cell line A549 treated with Si135 (see supplementary
figure S6). The effects with this dual kinase inhibitor were less
pronounced. The network around the target kinases involves seven
molecules. Notably, expression of the tumour marker Ceacam6 and
Cdcp1 were upregulated as was prostaglandin synthase 2 (Ptgs2)
that might lead to a modified arachidonic acid metabolism
pertinent to the respiratory epithelium [49]. Furthermore, altered
expression of the cell adhesion molecule laminin beta 3 (Lamb3),
the matrix-associated binding protein discs, large (Drosophila)
homolog-associated protein 4 (Dlgap4) and versican (Vcan) signified
the effects of this dual kinase inhibitor on cell adhesion.
Cell line A2C12 treated with Si135 (see supplementary
figure S7). Considering the network around the target kinases,
the dual specificity phosphatase 1 (Dusp1) comes into focus that
represses signalling through the MAPK kinases. Further cell
growth regulating phosphatases are myotubularin 1 (Mtm1) and
protein tyrosine phosphatase receptor type G (Ptprg) that were
upregulated. Despite the considerable differences in the treatment
effects of Si162 and Si135 there are also commonalities. The Wnt
receptor Sfrp1 is induced after treatment with both substances as
was Gadd45a and matrix metallopeptidase Mmp13.
Cell line GammaA3 treated with Si135 (see supple-
mentary figure S8). The effects of Si135 on the cell line
GammaA3 are similar to those described for A2C12 and A549.
An induced gene expression of matrix metallopeptidases Mmp3
and Mmp13, the centromer protein A (Cenpa) and integrin alpha 6
(Itga6) suggests interference with extracellular matrix and integrin
receptors. Notably, neural guanine exchange factor (Ngef), that
directly interacts with Src, was induced at the transcript level. In
addition, genes involved in cell growth and proliferation such as
the mitogen-activated protein kinase 8 interacting protein 1
(Mapk8ip1) which prevents MAPK8-mediated activation of
transcription factors and interacts directly with Src and Egfr was
repressed. Tyrosine-3-monooxygenase activating protein (Ywhaz)
as well as transforming growth factor beta regulator 4 (Tbrg4) and
Catenin delta 1 (Ctnnd1) which also participate in signal
transduction were repressed as was regulation of collagen, type
I, alpha 1 (Col1a1) and hyaluronan synthase 2 (Has2) which are
crucial for cell migration and cell growth.
Cell line CaCo2 treated with Si135 (see supplementary
figure S9). As observed with other cancer cell lines the tumour
markers Ceacam6 as well as Ceacam1 were upregulated in cell line
CaCo2. The latter is described as mediator in cell adhesion in
processes like angiogenesis, apoptosis and metastasis [50]. The
induction of the tumour markers fits with the repression of
metastasis suppressor 1 (Mtss1). In contrast, thrombospondin 1
(Thbs1), that is associated with tumour growth and angiogenesis,
was downregulated and there was modulation of the cytoskeleton
as evidenced by altered gene expression of laminin gamma 2
(Lamc2), filamin C gamma (Flnc), tubulin alpha 1a (Tuba1a) and
actin gamma 2 (Actg2). Treatment of this cell line with Si135
induced expression of Cdkn1a, Cav1 and Dusp1, that control cell
cycle and progression, while Cdc25c and the survival factor Birc5
were downregulated. The induction of DNA-damage inducible
transcript 3 (Ddit3), a transcription factor for expression of DNA
repair genes, might be an adaptive response to programmed cell
death in tumour cells.
Cell line HepG2 treated with Si135 (see supplementary
figure S10). When compared with lung cancer cell lines, the
human hepatoma cell line HepG2 differed in its response to
treatment with Si135 and included upregulated insulin-like growth
factor (Igf) and integrin-linked kinase (Ilk) that are reported to be
induced in hepatocellular carcinoma [51]. The network around
the target molecules c-Src and c-Abl contains only proteins with
increased gene expression. Interestingly, the heteronuclear
ribonucleoprotein R (Hnrnpr), involved in many different
functions including transport of pre-mRNA from the nucleus to
cytoplasm, was induced by Si135 treatment. An induction of
protein tyrosine kinase 2 (Ptk2) and phosphoinositol-3-kinase class
2 alpha (Pik3c2a) was also observed. The latter is a cytoplasmic
tyrosine kinase belonging to the Src-family kinases and is activated
by Src through phosphorylation [52]. Pik3c2a is involved in various
signal cascades like proliferation and migration. Additionally
induced genes were cell cycle controlling proteins Dusp1 and
neural precursor cell expressed, developmentally down regulated 9
(Nedd9) and Tensin 1 (Tns1) that is involved in cytoskeleton
organization.
Discussion
The development of effective and targeted therapies for the
treatment of cancer remains the challenge to society and is
frequently confounded by chemoresistance resulting in low rates of
remission. There is a need for improved treatment strategies and
dual kinase inhibitors targeting tumour cells may provide the
means to combat cancer. Here we report the effects of a family of
dual c-Src/c-Abl tyrosine kinase inhibitors with a pyrazolo[3,4-d]-
pyrimidine scaffold which we found to be active against different
solid tumour cell lines that also express various cancer stem cell
markers.
Notably, by performing genome-wide expression analysis, the
molecular activities beyond dual kinase inhibitors could be
hypothesised. All compounds clearly inhibited activity of the
kinases c-Abl and c-Src in the nanomolar range, while for 15 out
of the 17 compounds tested, IC50 values for cell viability were in
the low micromolar range. Apart from the changes in viability and
morphology, shifts in the cell cycle were observed, which is
consistent with an arrest in G0/G1-phase or at G2/M transitions.
A highly induced caspase 3 and 7 activity was verified after 24 h,
but the efficiency of individual compounds differed amongst single
cancer cell lines. Upon treatment with the dual kinase inhibitors a
remarkable repression of EGFR was observed and this tyrosine
kinase in considered to be upstream of the c-Src kinase.
Importantly, inhibition of EGFR would be of major therapeutic
advantage, such as in patients with lung cancer where EGFR is
frequently hyperactive, as will be discussed below.
c-Src/c-Abl dual kinase inhibitors induce cell cycle arrest
The investigated experimental drugs led to an cell cycle arrest in
the G0/G1-phase, except for Si162 that caused an G2/M-arrest
while flow cytometry analysis allowed no firm conclusions on the
checkpoint regulation, the microarray and Western blot data clearly
evidenced the G2/M checkpoint to be activated if DNA damage
occurred in late S- or G2-phase. Thus, cell cycle is halted to allow
the repair of damaged DNA. The activation of the checkpoint is
decisively dependent on the inhibition of Cdc2. This kinase is
activated by phosphorylation on residue Thr161 of Cdk-activating
kinase(CAK) and bydephosphorylation of phosphataseCdc25C on
residues Tyr15 and Thr14. Note, Cdc25C is phosphorylated on
residue Ser216 by checkpoint kinases Chk1 and Chk2, therefore
representing a binding site for 14-3-3bef. The complex of Cdc25C
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Consequently,Cdc2remainsinactiveand thecellsarrestinG2[53].
Furthermore, p53 is stabilized by phosphorylation and activates
transcription of Gadd45 and p21Cip that prevent the activation of
Cdc2/cyclinB. Additionally, p53 acts as transcriptional repressor of
Cdc2 and Cyclinb [54]. The G2/M checkpoint activation fits the
experimental observations. At the protein level a clear reduction of
Cdc2 could be demonstrated (Fig. 2). The reduced gene expression
of Cdc2 and Cdc25b/c as well as the high protein level of p53 and the
induced expression of Gadd45a and p21Cip1 provides clear evidence
for the G2/M checkpoint activation.
The arrest in G0/G1 phase and induction of apoptosis caused
by all other experimental dual kinase inhibitors, has also been
observed with the dual kinase inhibitors dasatinib [55,56] or
ZD6474 [57].
Influences of c-Src inhibition on up and downstream
interacting partners
Src-family kinases are signal transducer, that are activated by
various classes of cell surface receptors. They interact with a variety of
molecules and mediate various cellular processes, thus mainly cell
growth, proliferation and cytoskeletal rearrangements incorporating
various signalling cascades like PDGFR, EGFR, FGFR, Integrins
and FAK [58]. An inhibition of c-Src could be observed after
treatment with Si162 in lung cancer cell lines. The level of
phosphorylated c-Src (Tyr416) decreased. Residue Tyr416 is
phosphorylated (and activated) by the autophosphorylation domain
of c-Src. Remarkable was the reduction of c-Src protein, but the gene
expression of Src was unaffected. Additionally, a reduction of EGFR
protein was evidenced. Notably, undue activation of the EGFR may
result from a combination of activating mutations in the kinase
domain and by overexpression of the receptor and its ligands [59]. In
addition to EGFR, c-Srcis also overexpressed inNSCLC.c-Src binds
the activated intracellular domain of EGFR and thus is temporarily
activated. c-Src activates EGFR by phosphorylation on residue
Tyr845 [60] that is located in the activation loop of the catalytic
domain. The phosphorylation is essential for complete catalytic and
biological activity [61]. The inhibition of c-Src showed an opposite
effect on EGFR and its downstream molecules STAT3 or STAT5. A
decreased protein expression of STAT5 could be verified in Western
blot analysis. Considering the results obtained from microarray
studies, it becomes obvious that Src and Egfr were not altered. This is
highly remarkable because a reduction in protein concentration
usually causes an induction in gene expression. Possibly, a feedback
mechanism is interrupted. In regards to the human hepatocellular
carcinoma cell line HepG2 an induction of Egfr gene expression was
observed, that verifies the elevated protein expression.
After treatment with Si135 as well as Si162 various genes
affecting cytoskeletal dynamics were altered in their expression. c-
Abl and c-Src activity are crucial for growth factor and integrin
signalling that induces reorganization of the cytoskeleton.
Important substrates are amongst others the Rho family, GTPases
and FAKs. The latter indicated also a decreased protein
expression after treatment with Si162 (Fig. 2 and 3. These
reactions are important for cell growth, migration and prolifera-
tion [62]. Taken collectively, the tested dual kinase inhibitors
efficiently inhibited cell growth and proliferation due to the
inhibition of the kinases c-Abl and c-Src.
Effect of the tested compounds on NSCLC, HCC and
colorectal carcinoma
The cell lines displayed considerable heterogeneity in response
to treatment with dual kinase inhibitors with Si162 yielding best
results with the human and murine lung tumour and hepatoma
cell lines, whereas the response to Si135 was equally in all cell
lines tested.
The IC50 values of the dual kinase inhibitors Si162 and Si135
were close to each other but their effects differed amongst the
cancer cell lines tested. For Si162, the inhibition of c-Abl and c-Src
caused an arrest at G2/M prior presumably due to repression of
Cdc2 (Cdk1), activation of p53 and induction of Gadd45a and
p21Cip1. In addition, the inhibition of c-Abl and c-Src caused
various effects to the cytoskeleton, leading to impaired spindle
formation.
Induced by DNA damage, c-Abl activates stress-activated
protein kinases (SAPK), as well as janus kinase and p38 MAPK.
Furthermore, an activation of p73 by phosphorylation through
p38 MAPK has been reported to foster an induction of apoptosis
[63]. As evidenced by Western blot, p73 was unchanged while p38
MAPK was decreased but p53 was strongly induced to suggest a
strong apoptotic signal, possibly due to its ability to interfere with
cytoskeleton dynamics.
Comparison of approved and experimental dual kinase
inhibitors
Since the discovery of the pathogenic Bcr-Abl translocation in
chronic myeloid leukaemia (CML) the number of rationally
designed drugs increased constantly. Imatinib (Glivec, STI571;
Novartis) was the first selective tyrosine kinase inhibitor approved
for the treatment of CML [64]. It is reported to inhibit the
chimeric Bcr/Abl kinase with an IC50 of 527 nM [65], whereas
the antiproliferative effect for leukaemia cells was in the
submicromolar range [66]. For comparison, imatinib’s IC50 was
determined between 10 and 30 mM for all investigated cell lines
after 24 h and 96 h of treatment. After repeated treatment of
tumour cell lines no decline of the IC50 was marked. Note, an IC50
of 2.7 and 5.0 mM was calculated for the dual kinase inhibitors
Si135 and Si162 after 96 h of treatment. Furthermore, imatinib is
a highly selective ATP-competitive inhibitor of Bcr/Abl, c-KIT
and platelet-derived growth factor receptor (PDGFR) [67], but the
IC50 ranges considerably amongst different tumour cell lines, since
imatinib interacts with non-conserved amino acid residues
neighbouring the ATP-binding site [68]. Imatinib treatment
causes the inhibition of the autophosphorylation of Bcr/Abl, c-
KIT and PDGFR, that in turn leads to antiproliferative effects and
induction of apoptotic activity [69]. The inhibition of Bcr/Abl
prevents an antiapoptotic pathway trough STAT5-mediated Bcl-
XL expression [70]. The downregulation of Bcl-XL is reported to
release cytochrome-c from the mitochondria, resulting in the
activation of caspase 3 [71].
Imatinib is approved for first-line treatment in CML [72], but
patients become resistant to this treatment due to point mutations
in the Abl gene resulting in substitutions of amino acid residues in
the Abl protein sequence. Additionally, mutations in various
domains of the Abl kinase were described [73]. Strategies to
overcome the resistance are imatinib dose-escalation or adjust-
ment based on pharmacokinetic assessment, that in turn can lead
to resistance mechanisms like the amplification of Bcr-Abl gene or
increased expression of ATP-binding cassette transporters (ABC)
for drug efflux [73].
Patients that fail on imatinib therapy are treated with dasatinib
(Sprycel, BMS354825), a small-molecule ATP-competitive inhib-
itor [74]. In contrast to imatinib, dasatinib is a dual specific c-Abl
and c-Src inhibitor and prevents activation of Bcr/Abl and Src
family kinases at an calculated IC50 of 1.83 nM. Furthermore,
dasatinib selectively inhibits the kinases PDGFR, c-KIT and
EPHB4. The antiproliferative effect of dasatinib to NSCLC cell
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10,000 nM [75]. This agrees well with the findings of the present
study and dasatinib after treatment for 96 h. Note, Si162 displays
similar activity to that of dasatinib. Especially for the murine
progenitor cell line GammaD12 and the human lung cancer cell
line A549 identical IC50 values with both agents at 800 nM and
5mM, respectively could be determined. Conversely, with the
murine tumour cells GammaA3, dasatinib has a 20-fold lower
IC50 than Si162.
Notably, cells treated with dasatinib show a cell cycle arrest in
G0/G1 phase and undergo apoptosis [76]. The inhibition of Src-
family kinases leads to changes in cell morphology due to missing
activation of the Src-interacting partners FAK, paxillin, p130Cas
as well as STAT3 and STAT5. Furthermore, dasatinib inhibits the
activation of EGFR that in turn prevents the activation of ERK
and AKT pathways [77], which strongly affects proliferation and
cell survival.
Dasatinib has a broad spectrum of antiproliferative effects to
overcome imatinib resistance. In contrast to imatinib it has less
rigid conformational requirements to Bcr/Abl, so it inhibits the
active and inactive conformation and overcomes most mutations
of Bcr/Abl. Additionally, dasatinib is not a substrate of ABC-
transporters [78].
Dasatinib is approved for the treatment of imatinib-resistant
CML and Philadelphia (Ph+) adult lymphoblastic leukaemia (ALL)
and may proof to be beneficial in solid tumours in regards to
migration and invasion [79]. Even though dasatinib exhibits high
potency, resistance to dasatinib was reported as well. A mutation
in amino acid residue 315 (Thr to Ile) can not be overcome by
dasatinib, as well as others [80].
Here we investigated dual kinase inhibitors which are
structurally related to the broadly used pyrazolo[3,4-d]pyrimidines
(PP1 and PP2) Src-family inhibitors. Indeed, PP2 inhibitors display
similar effects as observed after treatment of tumour cell lines with
the experimental drugs Si135 and Si162, including inhibition of c-
Src, followed by a reduced activation of cortactin and paxillin
[81]. The structures of PP2, Si135 and Si162 differ in the
formation of their substitutes, however, it is not trivial to predict
the conformation of the experimental drug in the ATP-binding site
of the kinase.
Compared to the approved leukemic anti-cancer agents
imatinib and dasatinib, our experimental dual kinase inhibitors
suggests a therapeutic advantage on various types of cancer.
Importantly, more than 20 clinical trials are ongoing to evaluate
the therapeutic efficiency of the dual kinase inhibitors imatinib and
dasatinib on various solid tumours under various therapeutic
regimes and treatment conditions, e.g. a combined administration
of dasatinib and ketoconazole to patients suffering on various solid
tumours [82] or the treatment of advanced NSCLC with dasatinib
and erlotinib [83].
As discussed above, the herein presented dual kinase inhibitors
modulate cytoskeleton dynamics to cause a change in morphology.
They also display strong inhibition of the EGFR protein, which is
a novel finding. Affecting EGFR is of great benefit in the combat
of cancer and possibly inhibiting kinases that phosphorylate EGFR
may provide the means to control, at least in part, expression of
the EGFR.
The characteristics of cell death between Si135 and Si162 might
in part be dependent on the different inhibitory effect on the
kinases c-Abl and c-Src. For Si135 a low Ki for c-Abl, but no
inhibition of c-Src was observed, while Si162 inhibits both kinases,
especially c-Src at a very low Ki value (Table 1). Further evidence
stems from the gene expression data with c-Src kinase affecting the
organization of the cytoskeleton as mediated by FAK, Akt and
ERK amongst others. However, the predominantly c-Abl inhibitor
Si135 induced cytoskeletal modifications as well, but much fewer
genes were regulated and less distinct effects on cell cycle
regulations were observed.
Together, the inhibition of the tyrosine kinases c-Abl and c-Src
suggests a high potential for treatment of solid cancers. The dual
kinase inhibitors were found active against a large panel of tumour
cell lines including human and murine lung, hepatoma and colon
cancer cell lines. Treatment with these experimental drugs led to
growth arrest and induction of apoptosis.
Methods
Chemistry
Starting materials were purchased from Aldrich-Italia (Milan,
Italy).
Melting points were determined with a Bu ¨chi 530 apparatus
and are uncorrected. IR spectra were measured in KBr with a
Perkin-Elmer 398 spectrophotometer.
1H NMR spectra were
recorded in a (CD3)2SO solution on a Varian Gemini 200
(200 MHz) instrument. Chemical shifts are reported as d (ppm)
relative to TMS as internal standard, J in Hz.
1H patterns are
described using the following abbreviations: s=singlet, d=dou-
blet, t=triplet, q=quartet, quint=quintex, sx=sextet, m=mul-
tiplet, br=broad. All compounds were tested for purity by TLC
(Merck, Silica gel 60 F254, CHCl3 as the eluant). Analyses for C,
H, N, S were within 60.3% of the theoretical value.
Synthesis of the dual kinase inhibitors
The synthesis of compounds 11–23 has already been reported
[84–87], while the synthesis of compounds 4 and 5 (Table 1) is
depicted in figure 5. The 1-(2-hydroxy-2-phenylethyl)-6-thioxo-
1,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 1, pre-
pared according to this procedure [88], was alkylated on the C6
sulphur atom using the appropriate alkyl bromide and anhydrous
K2CO3 in anhydrous dimethylformamide (DMF) at room
temperature. The 6-alkylthio derivatives 2a–b were in turn
chlorinated with the Vilsmeier complex (POCl3:DMF, 1:1, 10
equiv), in CHCl3 at reflux for 8 h to obtain the dichloro analogues
3a–b in good yield after chromatography purification on a Florisil
column. The desired pyrazolo[3,4-d]pyrimidine 4 was obtained by
reaction between 3a and 3-chloroaniline in ethanol at reflux for
4 h (Method A) while the analogue 5 was obtained by reaction of
3b with phenylethylamine in anhydrous toluene at rt for 2 days
(Method B).
Compounds 9 and 10 were prepared as described in figure 6.
The 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carbox-
amide 6, prepared according to our procedure [89], was treated
with sodium ethoxide and ethyl acetate in absolute ethanol at
reflux for 6 h to afford the 1-(2-hydroxy-2-phenylethyl)-6-methyl-
1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 7, that was in
turn chlorinated with the Vilsmeier complex (POCl3:DMF, 1:1,
30 equiv), in refluxing CHCl3 at reflux for 12 h to obtain the
dichloro derivative 8. Reaction of the latter with the suitable
aniline in absolute ethanol at reflux for 4 h gave the desired
compounds 9 and 10 (method A).
General procedure for the synthesis of 6-(alkylthio)-1-(2-
hydroxy-2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyr-
imidin-4-ones (2a–b). Amixtureof1-(2-hydroxy-2-phenylethyl)-
6-thioxo-1,5,6,7-tetrahydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 1
(2.88 g, 10 mmol), the appropriate alkyl bromide (10.14 mmol) and
anhydrous K2CO3 ( 1 . 3 8g ,1 0m m o l )i na n h y d r o u sD M F( 1 0m l )
was stirred at room temperature for 8 h. The mixture was poured in
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recrystallized from absolute ethanol to afford 2a–b as white solids.
2a. Yield 37%, mp 194–195uC.
1H NMR: d 1.44 (d, J=6.2,
6H, 2CH3), 3.90 (d, 1H, OH, disappears with D2O), 3.98 (sept,
J=6.2, 1H, CHS), 4.38–4.48 and 4.50–4.58 (2m, 2H, CH2N),
5.19–5.22 (m, 1H, CHOH), 7.24–7.37 (m, 5H Ar), 8.06 (s, 1H, H-
3), 11.06 (br s, 1H, NH disappears with D2O). IR (cm
21): 3300–
3100 (NH+OH), 1704 (CO). Anal. (C16H18N4O2S) C, H, N, S.
2b. Yield 55%, mp 213–214uC.
1HN M R :d 1.42–1.74 and
1.94–2.27 (2m, 8H, 4CH2 cyclopentyl), 3.76–3.97 (m, 1H, CHS),
4.17–4.42 (m, 2H,CH2N), 4.92–5.12 (m, 1H,CHOH), 5.57 (d, 1H,
OH disappears with D2O), 7.03–7.28 (m, 5H Ar), 7.87 (s, 1H, H-3),
12.19 (br s, 1H, NH disappears with D2O). IR (cm
21): 3150–2850
(NH+OH), 1703 (CO). Anal.(C18H20N4O2S) C, H, N, S.
General procedure for the synthesis of 6-(alkylthio)-4-
chloro-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimi-
dines (3a–b). The Vilsmeier complex, previously prepared from
POCl3 ( 1 . 5 3g ,1 0m m o l )a n da n h y d r o u sD M F( 0 . 7 3g ,1 0m m o l )w a s
added to a suspension of the appropriate compound 2a–b (1 mmol) in
CHCl3 (50 ml). The mixture was refluxed for 8 h. The solution was
washed with iced water (2620 ml), dried (MgSO4), filtered, and
concentrated under reduced pressure. The crude oil was purified by
column chromatography (Florisil, 100–200 mesh) using diethyl ether
as the eluant, to afford the pure products 3a–b as white solids.
3a. Yield 74%, mp 67–68uC.
1H NMR: d 1.45 (d, J=6.2,
3H, CH3), 1.49 (d, J=6.2, 3H, CH3), 4.00 (sept, J=6.2, 1H,
CHS), 4.74–4.82 and 4.88–4.97 (2m, 2H, CH2N), 5.45–5.55 (m,
1H, CHCl), 7.21–7.50 (m, 5H Ar), 8.00 (s, 1H, H-3). Anal.
(C16H16N4Cl2S) C, H, N, S.
3b. Yield 63%, mp 70–71uC.
1HN M R :d 1.54–1.85 and 2.10–
2.32 (2m, 8H, 4CH2cyclopentyl), 3.93–4.07 (m, 1H, CHS), 4.67–4.80
and 4.82–4.97 (2m, 2H, CH2N), 5.38–5.50 (m, 1H, CHCl), 7.19–7.42
( m ,5 HA r ) ,7 . 9 4( s ,1 H ,H - 3 ) .A n a l .( C 18H18N4Cl2S) C, H, N, S.
Synthesis of 1-(2-hydroxy-2-phenylethyl)-6-methyl-1,5-dihy-
dro-4H-pyrazolo[3,4-d]pyrimidin-4-one (7). To a solution of
5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxamide 6
(2.46 g, 10 mmol) in absolute ethanol (90 mL), a solution of sodium
ethoxide prepared from sodium (1.84 g, 80 mmol) and absolute
ethanol (30 mL) and ethyl acetate (7.93 g, 90 mmol) were added.
The mixture was refluxed for 6 h; after cooling, ice water was added
and the solution was acidified with 3% acetic acid. The precipitated
solid was filtered, washed with water and recrystallized from absolute
ethanol to afford compound 7 as a white solid, yield 60%, mp 253–
254uC.
1H NMR: d 2.25 (s, 3H, CH3), 4.07–4.20 and 4.27–4.42 (2m,
2H, CH2N), 4.92–5.06 (m, 1H, CHOH), 5.52 (br s, 1H, OH
disappears with D2O), 7.10–7.30 (m, 5H Ar), 7.90 (s, 1H, H-3), 11.91
(br s, 1H, NH disappears with D2O). IR (cm
21): 3400–3150
(NH+OH), 1660 (CO). Anal. (C14H14N4O2)C ,H ,N .
Figure 5. Synthesis of compounds 4 and 5. Reagents and conditions: a) RBr, K2CO3, DMF, r.t, 8h; b) POCl3/DMF, CHCl3, reflux, 8h; c) Method A: 3-
chloroaniline, ethanol, reflux, 4h (for 4); Method B: phenylethylamine, toluene, r.t.,48h (for 5).
doi:10.1371/journal.pone.0014143.g005
Figure 6. Synthesis of compounds 9 and 10. Reagents and conditions: a) EtONa, CH3COOEt, ethanol, reflux, 6h; b) POCl3/DMF, CHCl3, reflux, 12h;
c) m-fluoro aniline (for 9) or m-chloro aniline (for 10), ethanol, reflux, 4 h.
doi:10.1371/journal.pone.0014143.g006
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1H-pyrazolo[3,4-d]pyrimidine (8). The Vilsmeier complex,
previously prepared from POCl3 (4.60 g, 30 mmol) and anhy-
drous DMF (2.20 g, 30 mmol) was added to a suspension of 1-
(2-hydroxy-2-phenylethyl)-6-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]
pyrimidin-4-one 7 (0.27 g, 1 mmol) in CHCl3 (10 ml). The mixture
was refluxed for 12 h. The solution was washed with water
(2620 ml), dried (MgSO4), filtered and concentrated under re-
duced pressure. The crude oil was purified by column chroma-
tography (Florisil, 100–200 mesh), using diethyl ether as the eluant,
toafford8asayellowoil,whichcrystallized standinginarefrigerator
by adding a 1:1 mixture of diethyl ether/petroleum ether (bp 40–
60uC) as a white solid, yield 67%, mp 96–97uC.
1HN M R :d 2.69 (s,
3H, CH3), 4.68–4.81 and 4.90–5.04 (2m, 2H, CH2N), 5.39–5.51 (m,
1H, CHCl), 7.16–7.41 (m, 5H Ar), 8.01 (s, 1H, H-3). Anal.
(C14H12N4Cl2)C ,H ,N .
General procedure for the synthesis of compounds 4, 5,
9, 10
Method A (4, 9, 10). To a solution of the appropriate 4-
chloro derivative 3b and 8 (10 mmol) in absolute ethanol (10 ml)
the appropriate aniline (20 mmol) was added and the mixture was
refluxed for 4 h. After cooling, the white solid was filtered, washed
with water and recrystallized from absolute ethanol.
4. Yield 54%, mp 237–238uC.
1H NMR: d 1.41–1.70 and
2.02–2.23 (2m, 8H, 4CH2 cyclopentyl), 3.87–4.03 (m, 1H, SCH),
4.62–4.73 (m, 2H, CH2N), 5.51–5.64 (m, 1H, CHCl), 7.03–7.10,
7.20–7.44, 7.52–7.63 and 8.00–8.09 (4m, 9H Ar), 8.23 (s, 1H, H-
3). IR (cm
21): 2937 (NH). Anal. (C24H23N5Cl2S) C, H, N, S.
9. Yield 58%, mp 269–270uC.
1HN M R :d 2.69 (s, 3H, CH3),
4.45–4.66 and 4.78–4.94 (2m, 2H, CH2N), 5.25–5.37 (m, 1H, CHCl),
7.00 (s, 1H, H-3), 7.14–7.58 (m, 9H Ar), 12.60 (br s, 1H, NH disap-
pears with D2O). IR (cm
21): 2966 (NH). Anal. (C20H17N5ClF) C, H, N.
10. Yield 55%, mp 245–246uC.
1H NMR: d 2.69 (s, 3H,
CH3), 4.55–4.72 and 4.80–4.98 (2m, 2H, CH2N), 5.27–5.39 (m,
1H, CHCl), 6.99 (s, 1H, H-3), 7.16–7.53 (m, 9H Ar). IR (cm
21):
3100 (NH). Anal. (C20H17N5Cl2)C ,H ,N .
Method B (5). To a solution of 3a (3.67g, 10 mmol) in
anhydrous toluene (10 ml) phenylethylamine (4.48 g, 40 mmol)
was added and the mixture was stirred at room temperature for
48 h. The organic phase was washed with water (2610 ml), dried
(MgSO4), filtered, and concentrated under reduced pressure. The
crude oil was crystallized by adding a 1:1 mixture of diethyl ether/
petroleum ether (bp 40–60uC), to afford compound 5 as a white
solid, yield 60%, mp 125–126uC.
1H NMR: d 1.45 (d, J=6.2, 3H,
CH3), 1.50 (d, J=6.2, 3H, CH3), 2.97 (t, J=6.8, 2H, CH2Ar),
3.83 (q, J=6.8, 2H, CH2NH), 3.91–4.08 (m, 1H, CHS), 4.63–
4.92 (m, 2H, CH2N), 5.45–5.58 (m, 1H, CHCl), 7.13–7.44 (m,
10H Ar), 7.67 (s, 1H, H-3). IR (cm
21): 3243 (NH). Anal.
(C24H26N5ClS) C, H, N, S.
Pharmacologic inhibitors, Enzymes and Proteins
The dual kinase inhibitors were prepared as a 10 mmol/l stock
solution in DMSO. The allocation of the substituents around the
pyrazolo[3,4-d]pyrimidine (Fig. 7) is listed in table 1.
Imatinib mesylate and Dasatinib were kindly supplied by
Selleck Chemicals LLC (Houston, TX, USA).
Baculovirus-produced recombinant purified his-tagged active
against human Src and Abl were purchased from Upstate (Lake
Placid, NY, USA).
Cell lines
Three human and eleven murine cancer cell lines were used.
The human NSCLC cell line A549 (ACC 107) and the human
colorectal carcinoma cell line CaCo2 (ACC 169) were obtained
from Deutsche Sammlung von Mikroorganismen und Zellkulturen
(DSMZ, Braunschweig, Germany). The human hepatocellular
carcinoma cell line HepG2 (HB-8065) was obtained from
American Type Culture Collection (Manassas, VA, USA). The
11 murine NSCLC cell lines were established as described recently
[90]. Cells were grown in monolayer cultures in DMEM
containing 10% foetal calf serum, 4 mmol/l L-glutamine and
2% Penicillin/Streptomycin at 37uC in a humidified atmosphere
of 95% air and 5% CO2.
Enzymatic assays
Src activity was measured in a filter-binding assay using the Src
Assay Kit (Upstate, Lake Placid, NY, USA), according to the
manufacturer’s protocol, using the specific Src peptide substrate
[KVEKIGEGTYGVVYK] in the presence of 0.125 pmol of Src
and 0.160 pmol of [c-
32P]ATP. Unlabelled ATP was added to
reach the final concentrations as indicated in the figure legends.
Abl activity was measured in a filter-binding assay using an Abl
specific peptide substrate (Abtide, Upstate). Reaction conditions
were (in a final volume of 10 ml): 25 mM Tris-HCl pH 7.5, 1 mM
DTT, 0.012 mM[ c-
32P]ATP, 0.022 mM c-Abl. Unlabelled ATP/
Mg
++ (1:1 M/M) mix was added to reach the final ATP
concentrations as indicated in the figure legends. Reactions were
incubated 10 min at 30uC.The samples (9 ml) were spotted on
paper cellulose filters which were washed according to the
manufacturer’s protocol. Filter-bound radioactivity was measured
by liquid scintillation with a Microbeta-Trilux apparatus (Perki-
nElmer, Waltham, MA, USA).
Kinetic analysis
Dose-response curves were computer simulated by fitting the
data to
E(%)~
Emax
1z
½I 
ID50
   ð1Þ
where E(%) is the fraction of the enzyme activity measured in the
presence of the inhibitor, Emax is the activity in the absence of the
inhibitor, [I] is the inhibitor concentration, and ID50 is the
inhibitor concentration at which E(%)=0.5Emax.
The ID50 were converted to Ki according to a competitive
mechanism with respect to the substrate ATP. The second
substrate of the reaction (the peptide) was kept at saturating
concentrations (4-fold higher than its Km). Since (i) the ATP
Figure 7. Structure of a pyrazolo-[3,4-d]-pyrimidine.
doi:10.1371/journal.pone.0014143.g007
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enzyme concentration was not negligible with respect to the ATP
concentration, the classical Cheng-Prusoff relationship was not
applicable. Consequently, Ki values were calculated according to
Ki~
ID50{
E0
2
  
E0{
S0
Km
{1
  
E0
0
B B @
1
C C A
ð2Þ
where S0 is the concentration of the competing substrate (ATP)
and E0 is the concentration of the enzyme. Each experiment
was done in triplicate and mean values were used for the
interpolation. Curve fitting was performed with the program
GraphPad Prism.
MTS-assay
Cell culture viability was monitored by CellTiter96H AQueous
One Solution Cell Proliferation Assay (Promega GmbH, Mann-
heim, Germany). The cells were seeded in triplicates in 96-well
microtitre plates and treated with the dual kinase inhibitors or
vehicle (0.2% DMSO). After 24 h or 96 h of treatment the MTS
tetrazolium reagent was added to the cells and incubated for 1 h.
Absorbance at 490 nm was assayed with a Victor3 Wallac 1420
Multilabel counter (PerkinElmer, Waltham, MA, USA). Back-
ground absorbance (medium only) was subtracted and the data
given as percent of DMSO treated vehicle controls.
Cell cycle analysis
Cells were seeded in triplicates in 12-well plates and treated at
the calculated IC50 concentrations of dual kinase inhibitors or
vehicle (0.2% DMSO) determined after daily treatment for 96 h.
CycleTEST
TM PLUS DNA Reagent Kit (Becton Dickinson
GmbH, Heidelberg, Germany) for cell cycle analysis was used,
according to the instructions of the manufacturer. Briefly, the cells
were harvested with trypsin, washed with PBS, and resuspended in
CycleTEST Buffer. The cells were centrifuged and resuspended in
solution A. After incubation for 10 min at room temperature,
solution B was added and incubated. After adding solution C, the
samples were incubated at 4uC protected from light. The samples
were stored on ice and protected from light until analysis by
FACScan flow cytometer (Becton Dickinson GmbH, Heidelberg,
Germany).
Caspase activity assay
The cells were seeded in triplicates in 96-well white-walled
microtitre plates and treated with the IC50 concentrations of dual
kinase inhibitors and vehicle for 24 h or 96 h. According to
instructions, Caspase-GloH 3/7 assay (Promega GmbH, Mann-
heim, Germany) was used for monitoring caspase activity. Briefly,
the same volume Caspase-Glo reagent as culture medium was
added and incubated 1 h at room temperature. Luminescence
was read with a Victor3 Wallac 1420 Multilabel counter
(PerkinElmer, Rodgau, Germany). Background absorbance
(medium only) was subtracted and the data given as percent of
vehicle controls.
Western blot
Western blot analysis was carried out after treatment of cell
cultures at IC50 concentrations for 96 h and compared to
untreated cells. For the Western Blot analysis, cells were rinsed
and lysed as previously described [91]. An amount of 25 mg
protein was used for SDS-PAGE. Antibodies for c-Abl (sc-131),
Actin (sc-1616), Cdc2-p34 (sc-8395), EPS15 (sc-1840), FAK (sc-
558), c-Fos (sc-52), p38 (sc-7972), p53 (sc-6243) and STAT5 (sc-
835x) were obtained from Santa Cruz (Santa Cruz Biotechnology,
Heidelberg, Germany), while c-Src (2109) and phospho-Src Y416
(2101) were purchased from Cell Signaling (Cell Signaling
Technology, Frankfurt a. M., Germany). The EGFR (06-847),
phospho-EGFR Y992 (07-821) and phospho-EGFR Y1045 (04-
284) stem from Upstate (Upstate, Schwalbach, Germany) and the
hnRNP-K (A300-676A) from Bethyl Labs (Bethyl Laboratories,
Montgomery, Texas, USA). Finally p73 (IMG-246) was supplied
by Imgenex (Imgenex, Hamburg, Germany). Depending on the
primary antibody the secondary antibodies were either horserad-
ish peroxidase-conjugated anti-mouse (AP 160P), anti-rabbit (AP
132P) or anti-sheep (AP 147P) (Chemicon, Schwalbach, Ger-
many).
Semi-quantitative analysis were carried out with Kodak 1D
Image Analysis Software in reference to the vehicle treated control
cells (see supplementary table S7).
Whole genome expression analysis
Cells were cultured in 25 cm
2 culture flasks and treated at IC50
concentrations of the dual kinase inhibitors for 96 h. The cells
were harvested and RNA was isolated using RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the instructions of the
manufacturer. The isolated RNA (250 ng) was processed further
using standard protocols as described recently [92] with the
exception of the 39 IVT Express Kit (Affymetrix, High Wycombe,
UK) that was utilized according to instructions. Quality control of
cRNA was done with the Agilent 2100 Bioanalyzer (Agilent Tech
according to manufacturer’s protocols. Following fragmentation,
cRNA of each sample was hybridized to Affymetrix GeneChipH
Mouse Genome 430 2.0 or Human Genome U133 Plus 2.0 and
scanned with an Affymetrix 3000 7G scanner.
The resultant data was normalized by Probe Logarithmic
Intensity Error Estimation (PLIER) algorithm. Statistical analysis
was carried out with the ArrayTrack software (National Center for
Toxicological Research/FDA, Jefferson, AR, USA) using SAM
algorithm.
Stem cell marker expression
The gene expression of the stem cell markers Cd34, Cd24a,
Cd44, Cd133, Thy1/Cd90, Pdpn, Nes and Dlg7 was determined as a
ratio of transcript expression when compared to healthy
respiratory epithelium of non-transgenic murine alveolar type II
cells. For human cancer cell lines HepG2, CaCo2 and A549 the
expression was determined relatively to healthy human hepato-
cytes, colorectal cells and bronchial epithelial cells, respectively.
Supporting Information
Figure S1 Network of cell line A549 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si162. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s001 (0.06 MB
PDF)
Figure S2 Network of cell line A2C12 around c-Abl, EGFR,
c-Met and c-Src after treatment with compound Si162.
Displayed are molecules that were adjusted after treatment
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EGFR, c-Met and c-Src. In detail the symbols mean: red
genes (repressed), green genes (induced), white genes (not
adjusted), arrows (direct interactions), broken arrows (indirect
interactions).
Found at: doi:10.1371/journal.pone.0014143.s002 (0.05 MB
PDF)
Figure S3 Network of cell line GammaA3 around c-Abl,
EGFR, c-Met and c-Src after treatment with compound Si162.
Displayed are molecules that were adjusted after treatment and
described in context with the tyrosine kinases A: c-Abl, B:
EGFR, C: c-Met and D: c-Src. In detail the symbols mean: red
genes (repressed), green genes (induced), white genes (not
adjusted), arrows (direct interactions), broken arrows (indirect
interactions).
Found at: doi:10.1371/journal.pone.0014143.s003 (0.20 MB
PDF)
Figure S4 Network of cell line CaCo2 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si162. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s004 (0.03 MB
PDF)
Figure S5 Network of cell line HepG2 around c-Abl, EGFR,
c-Met and c-Src after treatment with compound Si162.
Displayed are molecules that were adjusted after treatment
and described in context with the tyrosine kinases A: c-Abl and
c-Src as well as B: EGFR and c-Met. In detail the symbols
mean: red genes (repressed), green genes (induced), white genes
(not adjusted), arrows (direct interactions), broken arrows
(indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s005 (0.13 MB
PDF)
Figure S6 Network of cell line A549 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si135. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s006 (0.02 MB
PDF)
Figure S7 Network of cell line A2C12 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si135. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s007 (0.02 MB
PDF)
Figure S8 Network of cell line GammaA3 around c-Abl, EGFR,
c-Met and c-Src after treatment with compound Si135. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s008 (0.03 MB
PDF)
Figure S9 Network of cell line CaCo2 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si135. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s009 (0.04 MB
PDF)
Figure S10 Network of cell line HepG2 around c-Abl, EGFR, c-
Met and c-Src after treatment with compound Si135. Displayed
are molecules that were adjusted after treatment and described in
context with the tyrosine kinases c-Abl, EGFR, c-Met and c-Src.
In detail the symbols mean: red genes (repressed), green genes
(induced), white genes (not adjusted), arrows (direct interactions),
broken arrows (indirect interactions).
Found at: doi:10.1371/journal.pone.0014143.s010 (0.03 MB
PDF)
Table S1 Cancer stem cell markers expressed in tested tumour
cell lines. Mean values in percent compared to non-transgenic and
appropriate controls.
Found at: doi:10.1371/journal.pone.0014143.s011 (0.01 MB
XLS)
Table S2 Calculated IC50 values after single treatment for 24 h.
Values are displayed in mmol/l. n.a.: not applicable. IC50.100 m-
mol/l.
Found at: doi:10.1371/journal.pone.0014143.s012 (0.02 MB
XLS)
Table S3 Calculated IC50 values after daily treatment for 96 h.
Values are displayed in mM. n.a.: not applicable, as IC50.20 mM.
except HepG2 where IC50.100 mM.
Found at: doi:10.1371/journal.pone.0014143.s013 (0.02 MB
XLS)
Table S4 Cell cycle regulation. The cells were treated with their
IC50 concentrations for 96 h. All values in %. N.a.: not
applicable.
Found at: doi:10.1371/journal.pone.0014143.s014 (0.03 MB
XLS)
Table S5 Selected significantly regulated genes after treatment
with dual kinase inhibitor Si135. Significantly regulated genes
were analyzed with SAM. All values are displayed as log2 of fold
change.
Found at: doi:10.1371/journal.pone.0014143.s015 (0.02 MB
XLS)
Table S6 Selected significantly regulated genes after treatment
with dual kinase inhibitor Si162. Significantly regulated genes
were analyzed with SAM. All values are displayed as log2 of fold
change.
Found at: doi:10.1371/journal.pone.0014143.s016 (0.03 MB
XLS)
Table S7 Semi-quantitative analysis of protein expression. Semi-
quantitative analysis of protein expression in reference of
untreated control cells. Band intensities obtained by Western blot
analysis were computed by Kodak 1D Image Analysis software. All
values are displayed as percent of the vehicle treated control cells.
N.A. not applicable.
Found at: doi:10.1371/journal.pone.0014143.s017 (0.02 MB
XLS)
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